Literature DB >> 2768132

Establishment of five human myeloma cell lines.

M Namba1, T Ohtsuki, M Mori, A Togawa, H Wada, T Sugihara, Y Yawata, T Kimoto.   

Abstract

Five human myeloma cell lines, KMM-1, KMS-5, KMS-11, KMS-12-PE, and KMS-12-BM, have been established at Kawasaki Medical School since 1980. As the KMS-12-PE and KMS-12-BM lines were obtained from the same patient, these five cell lines have been derived from four patients with multiple myeloma. The five myeloma cell lines are stably growing at present in RPMI 1640 medium supplemented with 10% fetal bovine serum. They can also grow in a defined culture medium without serum. That these cell lines were human myeloma cells was confirmed by the following findings. Ultrastructurally, all five cell lines showed features characteristic of plasma cells. KMM-1 and KMS-11 cells secreted lambda and kappa chains into the culture medium, respectively, but the other cell lines produced no immunoglobulins. KMM-1 expressed cytoplasmic lambda antigen, KMS-5 showed cytoplasmic delta, and KMS-11 expressed surface kappa, whereas KMS-12-PE and KMS-12-BM cells showed no surface or cytoplasmic immunoglobulins. Regarding reaction with a monoclonal plasma cell antibody (PCA-1), four of the five lines were positive, the exception being KMS-5. Another monoclonal antibody (CD38), which also recognizes plasma cells, responded to KMM-1, KMS-12-PE, and KSM-12-BM. KMS-5 cells expressed acute lymphoblastic leukemia antigens (CALLA). These data suggest that such lines as KMM-1, KMS-11, KMS-12-PE, and KMS-12-BM represent later stages of B-cell differentiation, and that KMS-5 represents a relatively early stage of B-cell differentiation. All the cell lines lacked Epstein-Barr virus nuclear antigen, showed abnormal karyotypes of human origin, and differed from each other in the isozyme patterns examined. Only KMS-5 was tumorigenic when transplanted subcutaneously into nude mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2768132     DOI: 10.1007/BF02623725

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  35 in total

1.  Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene.

Authors:  A F Gazdar; H K Oie; I R Kirsch; G F Hollis
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

2.  Cell growth kinetics of cultured human myeloma cell lines, KMM-1 and KMS-5.

Authors:  T Ohtsuki; Y Yawata; M Namba
Journal:  Nihon Ketsueki Gakkai Zasshi       Date:  1988-09

3.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

4.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

5.  Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes.

Authors:  D E Joshua; R Ioannidis; R Brown; S E Francis; J Gibson; H Kronenberg
Journal:  Am J Hematol       Date:  1988-09       Impact factor: 10.047

6.  The nature of cells generating human myeloma colonies in vitro.

Authors:  A W Hamburger; M B Kim; S E Salmon
Journal:  J Cell Physiol       Date:  1979-02       Impact factor: 6.384

7.  Establishment of a new human myeloma cell line (U-2030) and selection of a hat-sensitive subline.

Authors:  H Jernberg; G Björklund; K Nilsson
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

8.  Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

Authors:  F Caligaris-Cappio; L Bergui; L Tesio; G Pizzolo; F Malavasi; M Chilosi; D Campana; B van Camp; G Janossy
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

9.  CALLA-positive myeloma: an aggressive subtype with poor survival.

Authors:  B G Durie; T M Grogan
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

10.  Establishment and characterization of an amylase-producing human myeloma cell line.

Authors:  H Matsuzaki; H Hata; M Takeya; K Takatsuki
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

View more
  24 in total

1.  Murine T cell leukemia line in suspension culture.

Authors:  C Mongini; C Waldner; I Roig; S E Hajos
Journal:  In Vitro Cell Dev Biol       Date:  1991-07

2.  An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Authors:  Tracy R Daniels; Elizabeth Ortiz-Sánchez; Rosendo Luria-Pérez; Rafaela Quintero; Gustavo Helguera; Benjamin Bonavida; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

3.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.

Authors:  Michelle Kiebala; Jolanta Skalska; Carla Casulo; Paul S Brookes; Derick R Peterson; Shannon P Hilchey; Yun Dai; Steven Grant; Sanjay B Maggirwar; Steven H Bernstein
Journal:  Exp Hematol       Date:  2014-10-22       Impact factor: 3.084

5.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Authors:  P L Bergsagel; M Chesi; E Nardini; L A Brents; S L Kirby; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.

Authors:  Teresa S Hawley; Irene Riz; Wenjing Yang; Yoshiyuki Wakabayashi; Louis Depalma; Young-Tae Chang; Weiqun Peng; Jun Zhu; Robert G Hawley
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

7.  Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.

Authors:  Olga Balague; Ana Mozos; Daniel Martinez; Luis Hernandez; Lluis Colomo; Jose Luis Mate; Julie Teruya-Feldstein; Oscar Lin; Elias Campo; Armando Lopez-Guillermo; Antonio Martinez
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

8.  Identification of agents that promote endoplasmic reticulum stress using an assay that monitors luciferase secretion.

Authors:  Nicole A Doudican; Shih Ya Wen; Amitabha Mazumder; Seth J Orlow
Journal:  J Biomol Screen       Date:  2013-12-26

9.  Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Authors:  Yawara Kawano; Shiho Fujiwara; Naoko Wada; Mikiko Izaki; Hiromichi Yuki; Yutaka Okuno; Kenichi Iyama; Hiroshi Yamasaki; Akira Sakai; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2012-07-04       Impact factor: 5.650

10.  Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.

Authors:  Tamer B Shabaneh; Sondra L Downey; Ayrton L Goddard; Michael Screen; Marcella M Lucas; Alan Eastman; Alexei F Kisselev
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.